Switching to an Oral GLP-1 for Maintenance: What Whitney Black Noticed

A daily GLP-1 pill can sound like a simpler way to maintain weight loss. Whitney Black’s experience shows why the decision involves more than replacing a weekly injection with a tablet. Convenience, fullness, blood sugar and cost all mattered, and they did not move in the same direction.

In Ana Reisdorf’s conversation with Black, a registered dietitian who lives with type 1 diabetes, Black describes switching from Zepbound to Foundayo and then returning to Zepbound. This is one person’s account of a supervised medication change. It cannot establish which drug will work best for someone else, but it offers specific questions to ask before making a switch.

Why a pill appealed during weight maintenance

Black says she had lost about 60 pounds and was maintaining that loss when she considered another option. She was paying out of pocket, so affordability mattered. She also liked the possibility of taking a pill without organizing her day around strict food or timing rules.

Foundayo contains orforglipron. Zepbound contains tirzepatide. They are different medicines, rather than oral and injectable versions of the same drug. The FDA’s Foundayo approval announcement identifies it as an oral GLP-1 receptor agonist for eligible adults with obesity or overweight. Its prescribing information allows administration with or without food.

For Black, that flexibility was useful, but daily remembering was a separate task. She already took other medicines at night and discussed her routine with her prescriber. Working from home made a lunchtime reminder manageable. A simpler formulation still had to fit the rest of her treatment.

Food noise and fullness did not change in the same way

The first week felt reasonably familiar. Later, Black noticed that she was eating beyond the point she expected to feel satisfied. She makes an important distinction: she did not necessarily experience a dramatic return of food noise. What changed most was the signal that a meal was enough.

She describes looking at a plate with protein and fiber and thinking that it should be satisfying. Her stomach could feel physically full while her mind continued asking for more. Increasing treatment under her clinician’s direction helped somewhat, she says, but did not recreate her previous experience.

That distinction makes a vague report such as “the medication isn’t working” more useful. What has changed: thoughts about food, physical hunger, comfortable fullness, portion size, side effects or something else? Black’s account does not prove a mechanism, but it shows why describing the experience precisely can help a care team assess it.

Blood sugar made this more than a weight experiment

Over roughly two months, Black reports gaining around 10 to 15 pounds. More concerning to her were higher blood sugars, rising insulin needs and glucose readings that took longer to come down. Those changes helped her decide that continuing the trial no longer felt worthwhile.

Her type 1 diabetes is essential context. She describes ongoing communication with her endocrinology team and substantial familiarity with her insulin pump. Readers should not turn her account into instructions for changing insulin, restarting medication or reproducing the doses discussed in the recording.

The Zepbound prescribing information warns that use with insulin can increase the risk of hypoglycemia. That is a reason for a clinician-directed monitoring and adjustment plan, not reassurance that another person’s settings will be safe. This conversation does not establish either medicine as a treatment for type 1 diabetes.

Returning to a familiar treatment was another transition

Black returned to Zepbound and says her blood sugar patterns and hunger cues began moving toward their previous state. She also experienced some renewed nausea and food aversions. Returning to something familiar did not mean skipping the adjustment process.

At the time of recording, she was allowing her body to settle rather than urgently trying to recover an exact scale number. That is an important part of the story: the practical goal was a treatment and eating pattern she could live with, alongside better glucose management. The episode is not a head-to-head trial or evidence that oral treatment cannot support maintenance.

Weight regain can trigger the wrong response

Ana describes how portion sizes can creep upward without a dramatic change in food choices. A familiar burrito bowl may go from half finished to three-quarters finished. The food has not changed, and the shift can be easy to miss.

Black encourages separating useful observation from blame. Her suggested response is to work with the situation you have: regular opportunities to eat, meals that include protein and fiber, and support for the distress that regain can bring. Panic-driven skipping and tighter food rules are not the solution she advocates.

She also distinguishes physical planning from the mental work of maintenance. A dietitian or therapist may help someone examine expectations and old dieting beliefs. For another long-term perspective, read Tara Rothenhoefer’s account of maintenance after years of GLP-1 treatment.

Questions to settle before changing medication

• What is the reason for switching, and how will we judge whether the change is helping?
• Which changes in hunger, symptoms, glucose or weight should prompt a message to the care team?
• How will this fit my other medicines, daily routine and insurance or out-of-pocket budget?
• What is the plan if the new treatment does not meet my needs?

Black’s experience is most useful as a model for noticing and reporting changes. A convenient option still has to work for the whole person. The choice, dose and transition plan belong with the prescribing team.